BNP Paribas Financial Markets Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

BNP Paribas Financial Markets acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 203,853 shares of the company's stock, valued at approximately $3,908,000. BNP Paribas Financial Markets owned about 0.26% of Viridian Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Viridian Therapeutics during the fourth quarter valued at $26,000. Foresite Capital Management VI LLC bought a new position in Viridian Therapeutics during the fourth quarter valued at about $38,000. AlphaQuest LLC raised its holdings in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after buying an additional 1,516 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Viridian Therapeutics during the fourth quarter valued at about $164,000.

Analyst Ratings Changes

VRDN has been the topic of several recent research reports. Royal Bank of Canada cut their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC cut their target price on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group cut their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $36.70.

Viridian Therapeutics Trading Down 3.4%

Viridian Therapeutics stock opened at $12.38 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The business's 50-day simple moving average is $13.53 and its 200-day simple moving average is $17.31. The firm has a market capitalization of $1.01 billion, a PE ratio of -2.87 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.